Spironolactone is a promising therapeutic option for alleviating

Spironolactone is a promising therapeutic option for alleviating remodeling after left ventricular restoration.”
“Objective: The aortic media lesion is a key pathologic feature in thoracic aortic dissection. To identify key proteins in aortic media lesions that may contribute to its pathogenesis, we performed proteomic studies to find differentially expressed proteins in the media from diseased and normal

thoracic aorta.

Methods: JIB04 supplier Ascending aortic segments were obtained from patients with thoracic aortic dissection (n = 8) and age-matched normal donors ( n 5 6). The differentially expressed proteins of their media tissues were analyzed by 2-dimensional electrophoresis and mass spectrometry, and verified by Western blotting. Oxidative stress was measured by functional assays in a larger sample size (15 patients and 10 controls).

Results: Image analysis of the protein profiles from 2-dimensional gels revealed 126 differentially expressed proteins, of which 26 were identified by mass spectrometry. Among them, extracellular superoxide dismutase, an enzyme involved in oxidative stress, was

selected for further studies. Western blotting showed that extracellular superoxide dismutase expression was more than 50% lower in patient samples than in controls (P < .001). Superoxide dismutase activity was consistently decreased (P <.001) and lipid peroxidation was increased (P = .019) in patient media homogenates compared with that in controls.

Conclusion: Our results indicate

that protein expression this website profiles in the aortic media from thoracic aortic dissection differ significantly from that of controls, which may provide important insights into the disease mechanisms. This study also suggests that increased oxidative stress may play an important role in the disease.”
“Objective: Complexity of mitral valve repair for myxomatous disease has led to low adoption. many We report initial experience with a new ring designed specifically for myxomatous disease, the Myxo-ETlogix ( Edwards Lifesciences LLC, Irvine, Calif).

Methods: From March 15, 2006, through November 19, 2007, 129 patients underwent mitral valve surgery for pure myxomatous disease, and 124 valves ( 96.1%) were repaired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring ( Edwards) in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic anterior motion and a larger orifice to accommodate elongated leaflets and decrease need for sliding plasty. Direct mitral valve measurements were made. Sizing was based on A2 height, and choice of ring type was based on unresected leaflet heights.

Results: There was no operative mortality or lasting perioperative morbidity.

Comments are closed.